Latest Conference Articles

STEP UP T2D data suggest semaglutide 7.2 mg's superiority to the 2.4 mg dose and placebo for proposed BMI and waist-to-height ratio treatment targets.

An EHR-based machine learning model predicted 10-year type 2 diabetes risk with near-ideal calibration in over 3 million adult patients.

Alexis Marcotte-Chénard, PhD, discusses his presentation on “exercise snacks” and how they can lower blood pressure and improve HbA1c in sedentary patients.

ACCESS phase 2b data show aleniglipron 120 mg produced 11.3% placebo-adjusted weight loss at 36 weeks, with continued reductions in the OLE.

Sood discusses emerging diabetes technologies, from automated insulin delivery to dual glucose-ketone monitoring, at ADA 2026.

The phase 3 TURING trial found rituximab slashed relapse rates in adults with minimal change disease and FSGS, offering a steroid-sparing alternative.

Teplizumab, which has recently seen a substantial label expansion into pediatric patients, is matching its safety and efficacy data in the clinic.

Phase 3 TETON-1 data show inhaled treprostinil reduced FVC decline by 130 mL and cut clinical worsening risk 33% in IPF patients over 52 weeks, according to Steven Nathan, MD.

5 interviews. 5 minutes. The asthma data from ATS 2026 your patients will be asking about.

Data suggest long-term extracorporeal photopheresis may reduce mortality risk in patients with chronic lung allograft dysfunction unresponsive to standard immunosuppression.

At EAC 2026, Dartmouth Children's Health allergist Marcus Shaker, MD, outlined a framework built on shared decision-making for families navigating food allergy in infancy.

View the top 6 trials to watch ahead of a star-studded ADA 2026.

Jonathan Bernstein, MD, discusses remibrutinib, c-kit inhibitors, and the current limits of biomarker-guided decision-making in chronic spontaneous urticaria.

Marcus Shaker, MD, discusses early allergen introduction, food allergy prevention, and the role of routine testing at EAC 2026.

Bernstein discussed treatment sequencing, biomarker use, and evolving chronic spontaneous urticaria management strategies during an interview at EAC 2026.

Bernstein discussed the evolving role of biomarkers in chronic spontaneous urticaria at EAC 2026.

In this Q&A, Tatiana V. Kudryashova, PhD, discusses new data presented at ATS 2026 that show silencing E2F2 suppresses hyperproliferation in PAH smooth muscle cells.

Igor Barjaktarevic, MD, discussed findings at ATS 2026, where the recombinant therapy outperformed weekly plasma-derived augmentation on key pharmacokinetic endpoints.

Oren Cohen, MD, discusses his research and points toward more clinically deployable cardiovascular risk tools for patients with OSA.

At ATS 2026, Couillard discussed a win ratio analysis showing dupilumab significantly improved remission outcomes, particularly among patients with elevated eosinophils and FeNO.

At ATS 2026, Sarath Raju, MD, discussed retrospective data linking SGLT2 inhibitor use to reduced 30-day readmissions in patients hospitalized for AE-COPD and diabetes.

At ATS 2026, Krunal Patel, MD, discussed early real-world data suggesting sotatercept may improve hemodynamics, RV remodeling, and functional outcomes in group 3 CLD-PH.

Brittany Duchene, MD, found that depressive symptoms were associated with twice the odds of poorly controlled asthma.

This interview highlights phase 3 findings from the SUNRISE study regarding tezepelumab and oral corticosteroid (OCS) reduction in patients with severe, OCS-dependent asthma.

A quantitative CT-based approach may help predict pneumothorax risk after bronchoscopic lung volume reduction, according to findings presented at ATS 2026.

ATS 2026 data presented by Jamey Moore, DO, suggest greater upfront corticosteroid dosing may shorten hospitalization in acute exacerbations of autoimmune-related ILD.

At ATS 2026, Njira Lugogo, MD, discussed PASSAGE data showing tezepelumab reduced severe asthma exacerbations in smokers and patients with comorbid COPD.

Jeffrey Thiboutot, MD, discussed efficacy advantages seen in the trial at ATS 2026.